tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Kay JE et al. Uptake of FK 506 by lymphocytes and erythrocytes. 1991 Transplant. Proc. pmid:1721269
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
O'Neill EA et al. The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. 1991 Transplant. Proc. pmid:1721298
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Kar S and Carr B Gene expression of FK 506-binding protein. 1991 Transplant. Proc. pmid:1721303
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Ishibashi M et al. Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. 1991 Transplant. Proc. pmid:1721330
Kawauchi M et al. Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. 1991 Transplant. Proc. pmid:1721331
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Fung J et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. 1991 Transplant. Proc. pmid:1721333
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
McCauley J et al. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. 1991 Transplant. Proc. pmid:1721362
Zeevi A et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. 1991 Transplant. Proc. pmid:1703341
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Alessiani M et al. Infections in adult liver transplant patients under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703345
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Starzl TE et al. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. 1991 Transplant. Proc. pmid:1703351
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Shapiro R et al. Kidney transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703352
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Carroll PB et al. Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. 1991 Transplant. Proc. pmid:1721394
Scantlebury V et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. 1991 Transplant. Proc. pmid:1721395
Carroll PB et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. 1991 Transplant. Proc. pmid:1721396
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Eidelman BH et al. Neurologic complications of FK 506. 1991 Transplant. Proc. pmid:1721398
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Langrehr JM et al. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. 1991 Transplant. Proc. pmid:1721425
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Ogasa N et al. Effect of FK 506 on growth of transplanted newborn rat intestine. 1991 Transplant. Proc. pmid:1721428
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Kitahara S et al. Lymphoproliferative disorders after FK 506. 1991 Lancet pmid:1708846
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Michnick SW et al. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. 1991 Science pmid:1709301
Van Duyne GD et al. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. 1991 Science pmid:1709302
Lim SM and White DJ The pharmacology of immunosuppression. 1991 Ann. Acad. Med. Singap. pmid:1709344
Rosen MK et al. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. 1991 Biochemistry pmid:1709363
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. 1991 Hepatology pmid:1709412
Hohlfeld R [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. 1991 Nervenarzt pmid:1709725
Kay JE et al. Inhibition of T and B lymphocyte proliferation by rapamycin. 1991 Immunology pmid:1709916
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Roat MI et al. Treatment of Cogan's syndrome with FK 506: a case report. 1991 Transplant. Proc. pmid:1721457
Carroll PB et al. The use of FK 506 in new-onset type I diabetes in man. 1991 Transplant. Proc. pmid:1721458
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Takada K et al. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. 1991 J. Pharmacobio-dyn. pmid:1713626
Jin YJ et al. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1713687
Murase N et al. Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. 1991 Surgery pmid:1714104
Lodish HF and Kong N Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. 1991 J. Biol. Chem. pmid:1714445
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690
Thomson AW The immunosuppressive macrolides FK-506 and rapamycin. 1991 Immunol. Lett. pmid:1717376
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691
Steeves M et al. In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. 1991 J. Pharm. Pharmacol. pmid:1717676
Hildebrandt A et al. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. 1991 Transplant. Proc. pmid:1703694
Unmasking immunosuppression. 1991 Lancet pmid:1717800
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063
Kumano K et al. FK 506-induced nephrotoxicity in rats. 1991 Transplant. Proc. pmid:1703696
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064
Kuroki H et al. Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1703697
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Lane WS et al. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. 1991 J. Protein Chem. pmid:1718307
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
James DG Which immunomodulator? 1991 Br J Clin Pract pmid:1718384
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701